Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf001 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Jingbo Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Corporation, Health Economics and Outcomes, Wilmington, DE 19803, United States. Hauptthemen laut MEDLINE: Polycythemia Vera, Thromboembolism, Hospitalization, Health Resources. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.
Abstract (Originalsprache)
Background
Healthcare resource utilization (HCRU) and costs are often elevated in patients with polycythemia vera (PV), and this patient population has an increased risk of developing thromboembolic events (TEs). This study describes HCRU, costs, and mortality during TE-related hospitalizations among patients with PV in a contemporary real-world setting in the United States. Patients and Methods This retrospective cohort study included adult inpatients with PV and TE discharged from 623 hospitals between January 1, 2017, and June 30, 2020 with a 2-year follow-up period after the first TE-related (index) hospitalization. Data were abstracted from the PINC AI Healthcare database, which includes 25% of US inpatient discharges.
Results
Among 3494 patients (index TE: arterial, 69.1%; venous, 27.1%; both, 3.7%), mean (SD) age was 70.7 (14) years, and most patients were male (58.6%), White (81.2%), with Medicare insurance (72.6%). Mean (SD) Charlson Comorbidity Index score was 3.2 (2.3). Mean total hospitalization costs were $24 403 during the index hospitalization (mean [SD] hospital length of stay [LOS], 7 [9] days). A third (n = 1150) of patients were admitted to the intensive care unit (mean cost, $29 342; mean [SD] LOS, 5 [7] days). During 30 days and 2 years of follow-up, the TE-related readmission rate was 6.4% and 20.0%, respectively. All-cause mortality was 6.2% during index hospitalization; an additional 4.7% occurred during the 2-year follow-up period.
Conclusion
Among patients with PV and TE, inpatient hospitalization HCRU, costs, and mortality were substantial. These findings highlight the importance of preventing TEs in the management of PV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Incyte Corporation, Health Economics and Outcomes, Wilmington, DE 19803, United States.
- PINC AI™ Applied Sciences, Premier Inc., Charlotte, NC 28277, United States.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
ORCID-Profile: Jingbo Yu, Harold Brown
Förderung
- Incyte Corporation
Zitieren
APA
Yu, J., Gayle, J., Rosenthal, N., Brown, H., Braunstein, E., & Pemmaraju, N. (2025). Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera. The Oncologist. https://doi.org/10.1093/oncolo/oyaf001
Vancouver
Yu J, Gayle J, Rosenthal N, Brown H, Braunstein E, Pemmaraju N. Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera. The Oncologist. 2025. doi:10.1093/oncolo/oyaf001
BibTeX
@article{Yu2025,
author = {Yu, Jingbo and Gayle, Julie and Rosenthal, Ning and Brown, Harold and Braunstein, Evan and Pemmaraju, Naveen},
title = {Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf001}
}
EUVIMED